GARDP was able to make progress in 2020 despite the challenges of the COVID-19 pandemic. This webinar highlighted efforts to advance antibiotic R&D in the midst of the pandemic and underscored the importance of investing in the development of new and improved treatments for drug-resistant infections that pose the greatest threat to health.

Several Philadelphia-area life sciences companies made significant progress this week with development of new drug candidates targeting heart disease and viral and bacterial pathogens including Covid-19. Here's a rundown.